Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04310020 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04310020 · ClinicalTrials.gov record · last posted 2026-08-24

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

StatusActive, Not Recruiting
PhasePhase 2
Started2021-01-13
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase II trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more cancer cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to test the safety and effectiveness of radiation therapy followed by atezolizumab and find out what side effects, if any, it has on patient's non-small cell lung cancer.

Protocol amendment history 2 changes detected by DataLookout

2026-08-25
Primary completion pushed: 2026-09-01 → 2027-06-01
2026-08-25
Completion pushed: 2026-09-01 → 2027-06-01
Trial Details
NCT Number NCT04310020
Lead Sponsor National Cancer Institute (NCI)
Conditions Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Enrollment 47 participants
Start Date 2021-01-13
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-24